MYD88 and B-cell chronic lymphocytic leukemia: In contrast, CLL with MYD88 nonhotspot mutations showed features more similar to CLL with WT MYD88. Neither L265P nor non-L265P MYD88 mutations showed an impact on time to first treatment.